• Explore /
  • Poster
  • / TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.

Abstract Video & Slides Poster

Authors

null

Benjamin T. Cooper

Perlmutter Cancer Center, New York University School of Medicine, New York, NY

Benjamin T. Cooper , Steven J. Chmura , Jason J. Luke , Stephen Lawrence Shiao , Reva K Basho , Wade Thomas Iams , David B. Page , Cong Li , Richard C. Gregory , Michael Shaw , Kristin Horn , John Gibbs , Vicky A. Appleman , Allison J. Berger , Adnan Abu-Yousif , Neil Lineberry , Kate Stumpo , Aymen Elfiky , Naamit Kurshan Gerber

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT04879849

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2698)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2698

Abstract #

TPS2698

Poster Bd #

336b

Abstract Disclosures

Similar Posters

First Author: Gerald Steven Falchook

First Author: Jennifer Robinson Diamond

First Author: Jordi Rodon Ahnert

First Author: David M. Cognetti